Hansa Biopharma Secures €115M Deal with SERB for Idefirix in Europe and MENA — Hansa Biopharma AB (publ)

Event summary

Hansa Biopharma closed a €115M licensing deal with SERB Pharmaceuticals for Idefirix in Europe and MENA, including a €110M upfront payment.
SERB assumes commercialization responsibility for Idefirix in solid organ transplantation across 12 countries and the MENA region.
The transaction strengthens Hansa's financial position ahead of a potential US launch of imlifidase, pending FDA approval by December 2026.
Hansa will transfer Market Authorization of Idefirix to SERB and support EMA review for full approval based on Post-Authorization Efficacy Study data.

The big picture

This deal marks a strategic shift for Hansa Biopharma, offloading commercialization responsibilities to a specialized partner while securing substantial upfront funding. The move aligns with broader industry trends of biotech companies leveraging partnerships to expand market reach and strengthen financial positions ahead of key regulatory decisions. SERB's extensive experience in rare diseases and medical countermeasures positions it as a strong commercialization partner, potentially accelerating Idefirix's market penetration.

What we're watching

Regulatory Milestones: Whether the EMA's review process for full approval of Idefirix will proceed smoothly based on the Post-Authorization Efficacy Study data.
US Market Entry: The pace at which Hansa can prepare for a potential US launch of imlifidase, contingent upon FDA approval by December 2026.
Commercial Execution: How SERB's expertise and resources will enhance the commercialization of Idefirix in Europe and MENA, addressing a significant unmet medical need.